The Melanoma Associated Antigen 3 pipeline drugs market research report outlays comprehensive information on the Melanoma Associated Antigen 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Melanoma Associated Antigen 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology which include the indications Non-Small Cell Lung Cancer, and Melanoma. It also reviews key players involved in Melanoma Associated Antigen 3 targeted therapeutics development with respective active and dormant or discontinued products.

The Melanoma Associated Antigen 3 pipeline targets constitutes close to 18 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 5, 1, 2, and 3 respectively. Similarly, the universities portfolio in Phase III, Phase I, Phase 0, and Preclinical comprises 1, 3, 1, and 1 molecule.

Melanoma Associated Antigen 3 overview

Melanoma-Associated Antigen 3, commonly known as MAGE-A3, serves as an activator of the ubiquitin ligase function of RING-type zinc finger-containing E3 ubiquitin-protein ligases. It also functions as a repressor of autophagy. This protein enhances the ubiquitin ligase activity of TRIM28 and stimulates the ubiquitination of p53/TP53 by TRIM28. Its proposed mechanism of action involves the recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. MAGE-A3 plays a role in embryonal development and may be associated with tumor transformation or certain aspects of tumor progression. In vitro studies have shown that it promotes cell viability in melanoma cell lines. Additionally, it is recognized as an antigen on melanoma cells by autologous cytolytic T-lymphocytes.

For a complete picture of Melanoma Associated Antigen 3’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.